Novartis AG

BATS-CHIXE:NOVNz Stock Report

Market Cap: CHF 182.1b

Novartis Valuation

Is NOVNz undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NOVNz when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NOVNz (CHF91.02) is trading below our estimate of fair value (CHF243.09)

Significantly Below Fair Value: NOVNz is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NOVNz?

Key metric: As NOVNz is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NOVNz. This is calculated by dividing NOVNz's market cap by their current earnings.
What is NOVNz's PE Ratio?
PE Ratio17.5x
EarningsUS$11.76b
Market CapUS$206.30b

Price to Earnings Ratio vs Peers

How does NOVNz's PE Ratio compare to its peers?

The above table shows the PE ratio for NOVNz vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.1x
AZN AstraZeneca
30.3x18.0%UK£155.4b
GSK GSK
21.2x21.9%UK£53.2b
HIK Hikma Pharmaceuticals
18.1x12.8%UK£4.1b
ROG Roche Holding
18.8x11.1%CHF 201.3b
NOVNz Novartis
17.5x7.0%CHF 182.1b

Price-To-Earnings vs Peers: NOVNz is good value based on its Price-To-Earnings Ratio (17.5x) compared to the peer average (22.1x).

Price to Earnings Ratio vs Industry

How does NOVNz's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies8PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NOVNz is good value based on its Price-To-Earnings Ratio (17.5x) compared to the European Pharmaceuticals industry average (20.6x).

Price to Earnings Ratio vs Fair Ratio

What is NOVNz's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NOVNz PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.5x
Fair PE Ratio33.8x

Price-To-Earnings vs Fair Ratio: NOVNz is good value based on its Price-To-Earnings Ratio (17.5x) compared to the estimated Fair Price-To-Earnings Ratio (33.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NOVNz forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 91.02
CHF 91.10
+0.09%
10.8%CHF 110.05CHF 73.28n/a18
Nov ’25CHF 95.47
CHF 91.10
-4.6%
10.8%CHF 110.05CHF 73.28n/a18
Oct ’25CHF 96.79
CHF 91.10
-5.9%
10.8%CHF 110.05CHF 73.28n/a18
Sep ’25CHF 102.28
CHF 91.10
-10.9%
10.8%CHF 110.05CHF 73.28n/a18
Aug ’25CHF 98.57
CHF 91.10
-7.6%
10.8%CHF 110.05CHF 73.28n/a18
Jul ’25CHF 96.78
CHF 91.10
-5.9%
10.8%CHF 110.05CHF 73.28n/a18
Jun ’25CHF 92.96
CHF 91.10
-2.0%
10.8%CHF 110.05CHF 73.28n/a18
May ’25CHF 89.24
CHF 91.10
+2.1%
10.8%CHF 110.05CHF 73.28n/a18
Apr ’25CHF 87.26
CHF 91.10
+4.4%
10.8%CHF 110.05CHF 73.28n/a18
Mar ’25CHF 90.18
CHF 91.10
+1.0%
10.8%CHF 110.05CHF 73.28n/a18
Feb ’25CHF 90.40
CHF 91.10
+0.8%
10.8%CHF 110.05CHF 73.28n/a18
Jan ’25CHF 84.65
CHF 90.87
+7.3%
10.1%CHF 106.76CHF 73.62n/a18
Dec ’24CHF 85.41
CHF 91.67
+7.3%
10.7%CHF 108.39CHF 72.86n/a18
Nov ’24CHF 85.17
CHF 95.14
+11.7%
10.5%CHF 111.59CHF 75.42CHF 95.4718
Oct ’24CHF 93.93
CHF 102.40
+9.0%
11.0%CHF 118.23CHF 81.87CHF 96.7918
Sep ’24CHF 89.29
CHF 100.83
+12.9%
9.8%CHF 114.09CHF 81.59CHF 102.2818
Aug ’24CHF 90.99
CHF 99.49
+9.3%
10.1%CHF 112.21CHF 80.24CHF 98.5717
Jul ’24CHF 89.98
CHF 97.84
+8.7%
9.8%CHF 110.68CHF 79.87CHF 96.7816
Jun ’24CHF 87.98
CHF 97.81
+11.2%
9.3%CHF 111.76CHF 80.71CHF 92.9619
May ’24CHF 91.21
CHF 95.31
+4.5%
9.5%CHF 108.68CHF 80.63CHF 89.2419
Apr ’24CHF 83.72
CHF 91.41
+9.2%
10.3%CHF 107.38CHF 79.23CHF 87.2619
Mar ’24CHF 78.63
CHF 92.36
+17.5%
10.6%CHF 107.98CHF 70.40CHF 90.1821
Feb ’24CHF 80.47
CHF 88.37
+9.8%
10.1%CHF 103.42CHF 69.57CHF 90.4021
Jan ’24CHF 83.81
CHF 86.89
+3.7%
11.4%CHF 103.77CHF 69.93CHF 84.6521
Dec ’23CHF 84.11
CHF 86.17
+2.5%
10.7%CHF 101.83CHF 70.18CHF 85.4121
Nov ’23CHF 80.71
CHF 89.60
+11.0%
11.0%CHF 107.25CHF 69.99CHF 85.1721

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

hVIVO

UK£161.9m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.24

7D

-20.1%

1Y

31.3%

Formycon

€820.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.05

7D

-1.4%

1Y

-23.9%

Regeneron Pharmaceuticals

US$82.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$741.73

7D

-9.3%

1Y

-6.8%